Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chimpanzee adenovirus + self-amplifying messenger RNA vaccine
- Development stage
- Unknown
- Lead developer
- Gritstone Oncology
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The chimpanzee adenovirus + self-amplifying messenger RNA (samRNA) vaccine is a heterologous prime-boost immunotherapy platform developed by Gritstone bio. The platform utilizes a chimpanzee adenovirus serotype 68 (ChAd68) vector to prime the immune system, followed by a boost with samRNA. This combination is designed to induce high-titer neutralizing antibodies and a robust, durable CD8+ T-cell response against targeted antigens. In oncology, the platform is applied through the GRANITE (individualized neoantigens) and SLATE (shared neoantigens) programs to treat advanced solid tumors, often in combination with immune checkpoint inhibitors like nivolumab and ipilimumab. The technology has also been adapted for infectious diseases, notably in the CORAL program for COVID-19, where it delivers SARS-CoV-2 spike and non-spike antigens to provide broad and lasting protection.
- Other names
- Individualized neoantigen vaccineHeterologous prime-boost vaccineChAd68 + samRNA vaccine
02
Targets
SARS-CoV-2 spikepMHC (Peptide-MHC complex family)CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on chimpanzee adenovirus + self-amplifying messenger RNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chimpanzee adenovirus + self-amplifying messenger RNA vaccine.